About Oncoceutics
Oncoceutics is a Healthcare company based in Philadelphia (United States) founded in 2009, and was acquired by Chimerix in January 2021. Clinical-stage drug development company focused on oncology. The company has 18 employees. Its focus areas include Life Sciences, Oncology, Drugs and Diversified. Its competitors include C4 Therapeutics, Erasca and Revolution Medicines; 3 of its 3 listed competitors have raised funding.
Company details
Oncoceutics is a clinical-stage drug development company focused on oncology. Oncoceutics is developing ONC201, an oral, small-molecule drug that acts against numerous tumor types by sparing healthy cells and targeting the most potent tumor suppressor pathways. The company is currently in clinical trials at cancer centers including Massachusetts General Hospital, Rutgers Cancer Institute of New Jersey, Fox Chase Cancer Center, and at the University of Texas MD Anderson Cancer Center. ONC201 is in multiple trials at various stages and several analogs with differentiated profiles in preclinical testing. ONC201 is an Imipridone- Imipridones are a novel class of small molecule anti-cancer compounds that possess a unique three-ring heterocyclic core structure with two substitutable basic amines. ONC201, which directly antagonizes a GPCR called DRD2
- Headquarters Philadelphia, United States
- Employees 18
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Website oncoceutics.com
- Social LinkedIn X
- Acquired by Chimerix (Jan 2021)
Funding Insights of Oncoceutics
- Total Rounds 5
- Last Round Grant — $1.69M
- Investors Count 2
All 5 funding rounds of Oncoceutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug 2017 | $1.69M | Grant | – | – | |
| Aug 2016 | $1.24M | Grant | – | – | |
| Oct 2015 | Series A | – | Spring Mountain Capital | – | |
| Sep 2015 | $4.83M | Grant | – | – | |
| Sep 2014 | Seed | – | Spring Mountain Capital | – |
3 investors in total: 3 institutional.
Investors in Oncoceutics
Oncoceutics has secured backing from 3 investors, including institutional and venture fund investors. Prominent investors backing the company include HHS, Chimerix and Spring Mountain Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital fund focused on multiple sectors | smcgrowthcapital.com | New York, United States | ||
Public health and human services are overseen by HHS. | 1953 | hhs.gov | ||
Antiviral oral therapeutics are developed for infectious diseases and cancers. | 2002 | chimerix.com | Durham, United Kingdom |
Investor details for Oncoceutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Oncoceutics
4 dated milestones of Oncoceutics across 12 years, from founding to its latest funding, stage changes and deals.
- Founded Oncoceutics is founded.
- Funding First funding round.
- Funding Latest funding round, Grant, of $1.7M.
- Exit Acquired by Chimerix.
Competitors of Oncoceutics
Oncoceutics has 3 listed competitors in our database, 3 of them funded. They include C4 Therapeutics, Erasca and Revolution Medicines.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| c4therapeutics.com | 2016 | Cambridge, United States | $223M | 121 | Small-molecule drugs for cancer treatment are developed via Degronimid platform. | |
| erasca.com | 2018 | San Diego, United States | $300M | 120 | Small molecule therapeutics for cancer treatment are developed. | |
| revmed.com | 2014 | Redwood, United States | $326.29M | 181 | Cancer therapies are developed using selective pathway inhibitors. |
Detailed competitors of Oncoceutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Oncology
3 companies that operate in the same segment as Oncoceutics (Oncology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Oncoceutics
Complete news archive for Oncoceutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Oncoceutics
Oncoceutics was founded in 2009 and raised its 1st funding round 5 years after it was founded.
Oncoceutics is headquartered in Philadelphia, United States. It is registered at Philadelphia, Pennsylvania, United States.
Oncoceutics has 18 employees.
Oncoceutics is a clinical-stage drug development company focused on oncology. Oncoceutics is developing ONC201, an oral, small-molecule drug that acts against numerous tumor types by sparing healthy cells and targeting the most potent tumor suppressor pathways. The company is currently in clinical trials at cancer centers including Massachusetts General Hospital, Rutgers Cancer Institute of New Jersey, Fox Chase Cancer Center, and at the University of Texas MD Anderson Cancer Center. ONC201 is in multiple trials at various stages and several analogs with differentiated profiles in preclinical testing. ONC201 is an Imipridone- Imipridones are a novel class of small molecule anti-cancer compounds that possess a unique three-ring heterocyclic core structure with two substitutable basic amines. ONC201, which directly antagonizes a GPCR called DRD2.
Oncoceutics's top competitors include C4 Therapeutics, Erasca and Revolution Medicines.
Oncoceutics has 3 investors. Key investors include HHS, Chimerix, and Spring Mountain Capital.
Yes. Oncoceutics was acquired by Chimerix in January 2021.